European Lung Cancer Congress 2022 (ELCC 2022)

First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC

Roshini Claire Anthony, 20220506180001

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

Adding durvalumab upfront to chemo ups long-term survival in SCLC

Pearl Toh, 20220505150100

Patients were threefold more likely to survive long term (beyond 3 years) when durvalumab was added to first-line chemotherapy, with or without tremelimumab, compared with those on chemotherapy alone, according to a post hoc analysis of long-term survivors (LTS) with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.

Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC

Audrey Abella, 20220430100000

In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.

Furmonertinib emerges as potential first-line option for EGFRm NSCLC

Roshini Claire Anthony, 20220422180001

Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.

SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC

Audrey Abella, 20220421100000

Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).